View Item 

Show simple item record

Incorporating financial toxicity considerations into clinical trial design to facilitate patient-centered decision-making in oncology
dc.contributor.authorGharzai, Laila A.
dc.contributor.authorJagsi, Reshma
dc.date.accessioned2023-04-04T17:40:54Z
dc.date.available2024-05-04 13:40:52en
dc.date.available2023-04-04T17:40:54Z
dc.date.issued2023-04-15
dc.identifier.citationGharzai, Laila A.; Jagsi, Reshma (2023). "Incorporating financial toxicity considerations into clinical trial design to facilitate patient-centered decision-making in oncology." Cancer 129(8): 1143-1148.
dc.identifier.issn0008-543X
dc.identifier.issn1097-0142
dc.identifier.urihttps://hdl.handle.net/2027.42/176053
dc.publisherWiley Periodicals, Inc.
dc.titleIncorporating financial toxicity considerations into clinical trial design to facilitate patient-centered decision-making in oncology
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbsecondlevelPublic Health
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/176053/1/cncr34677_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/176053/2/cncr34677.pdf
dc.identifier.doi10.1002/cncr.34677
dc.identifier.sourceCancer
dc.identifier.citedreferenceUbel PA, Abernethy AP, Zafar SY. Full disclosure—out-of-pocket costs as side effects. N Engl J Med. 2013; 369 ( 16 ): 1484 - 1486. doi: 10.1056/NEJMp1306826
dc.identifier.citedreferenceXie W, Regan MM, Buyse M, et al. Event-free survival, a prostate-specific antigen-based composite end point, is not a surrogate for overall survival in men with localized prostate cancer treated with radiation. J Clin Oncol. 2020; 38 ( 26 ): 3032 - 3041. doi: 10.1200/JCO.19.03114
dc.identifier.citedreferenceGharzai LA, Jiang R, Wallington D, et al. Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis. Lancet Oncol. 2021; 22 ( 3 ): 402 - 410. doi: 10.1016/S1470-2045(20)30730-0
dc.identifier.citedreferenceGyawali B, Rome BN, Kesselheim AS. Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study. BMJ. 2021; 374: n1959. doi: 10.1136/bmj.n1959
dc.identifier.citedreferenceReview of the FDA’s accelerated approval pathway. US Department of Health and Human Services. Accessed March 25, 2022. https://oig.hhs.gov/reports-and-publications/workplan/summary/wp-summary-0000608.asp#:~:text=the%20accelerated%20approval%20pathway%20allows,to%20predict%20a%20clinical%20benefit
dc.identifier.citedreferenceFDA grants accelerated approval for Alzheimer’s drug. US Food and Drug Administration. Accessed March 25, 2022. https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-drug
dc.identifier.citedreferenceFallowfield L. Participation of patients in decisions about treatment for cancer. BMJ. 2001; 323 ( 7322 ): 1144. doi: 10.1136/bmj.323.7322.1144
dc.identifier.citedreferenceSpiegelhalter D, Pearson M, Short I. Visualizing uncertainty about the future. Science. 2011; 333 ( 6048 ): 1393 - 1400. doi: 10.1126/science.1191181
dc.identifier.citedreferenceBryant AK, Sankar K, Strohbehn GW, et al. Timing of adjuvant durvalumab initiation is not associated with outcomes in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2022; 113 ( 1 ): 60 - 65. doi: 10.1016/j.ijrobp.2021.12.176
dc.identifier.citedreferenceJagsi R, Schipper M, Mietzel M, et al. The Michigan Radiation Oncology Quality Consortium: a novel initiative to improve the quality of radiation oncology care. Int J Radiat Oncol Biol Phys. 2022; 113 ( 2 ): 257 - 265. doi: 10.1016/j.ijrobp.2022.01.048
dc.identifier.citedreferenceWen L, Divers C, Lingohr-Smith M, Lin J, Ramsey S. Improving quality of care in oncology through healthcare payment reform. Am J Manag Care. 2018; 24 ( 3 ): e93 - e98.
dc.identifier.citedreferenceLi R, Yashar C, Thaker N, Beriwal S, Glaser S. Radiation oncology alternative payment model (APM): an introduction and primer for the proposed rule for practices and providers. Pract Radiat Oncol. 2021; 11 ( 1 ): e22 - e29. doi: 10.1016/j.prro.2020.04.011
dc.identifier.citedreferenceRatain MJ, Goldstein DA, Lichter AS. Interventional pharmacoeconomics—a new discipline for a cost-constrained environment. JAMA Oncol. 2019; 5 ( 8 ): 1097 - 1098. doi: 10.1001/jamaoncol.2019.1341
dc.identifier.citedreferenceLansdorp-Vogelaar I, Jagsi R, Jayasekera J, Stout NK, Mitchell SA, Feuer EJ. Evidence-based sizing of non-inferiority trials using decision models. BMC Med Res Methodol. 2019; 19 ( 1 ): 3. doi: 10.1186/s12874-018-0643-2
dc.identifier.citedreferencede Souza JA, Yap BJ, Wroblewski K, et al. Measuring financial toxicity as a clinically relevant patient-reported outcome: the validation of the COmprehensive Score for financial Toxicity (COST). Cancer. 2017; 123 ( 3 ): 476 - 484. doi: 10.1002/cncr.30369
dc.identifier.citedreferenceJagsi R, Ward KC, Abrahamse PH, et al. Unmet need for clinician engagement regarding financial toxicity after diagnosis of breast cancer. Cancer. 2018; 124 ( 18 ): 3668 - 3676. doi: 10.1002/cncr.31532
dc.identifier.citedreferenceZafar SY, Abernethy AP. Financial toxicity, part I: a new name for a growing problem. Oncology (Williston Park). 2013; 27 ( 2 ): 80 -149.
dc.identifier.citedreferenceYabroff KR, Dowling EC, Guy GP Jr, et al. Financial hardship associated with cancer in the United States: findings from a population-based sample of adult cancer survivors. J Clin Oncol. 2016; 34 ( 3 ): 259 - 267. doi: 10.1200/JCO.2015.62.0468
dc.identifier.citedreferenceEll K, Xie B, Wells A, Nedjat-Haiem F, Lee PJ, Vourlekis B. Economic stress among low-income women with cancer: effects on quality of life. Cancer. 2008; 112 ( 3 ): 616 - 625. doi: 10.1002/cncr.23203
dc.identifier.citedreferenceTrogdon JG, Baggett CD, Gogate A, et al. Medical costs associated with metastatic breast cancer in younger, midlife, and older women. Breast Cancer Res Treat. 2020; 181 ( 3 ): 653 - 665. doi: 10.1007/s10549-020-05654-x
dc.identifier.citedreferenceJagsi R, Pottow JA, Griffith KA, et al. Long-term financial burden of breast cancer: experiences of a diverse cohort of survivors identified through population-based registries. J Clin Oncol. 2014; 32 ( 12 ): 1269 - 1276. doi: 10.1200/JCO.2013.53.0956
dc.identifier.citedreferenceWang L, Hong BY, Kennedy SA, et al. Predictors of unemployment after breast cancer surgery: a systematic review and meta-analysis of observational studies. J Clin Oncol. 2018; 36 ( 18 ): 1868 - 1879. doi: 10.1200/JCO.2017.77.3663
dc.identifier.citedreferenceZafar SY, Peppercorn JM, Schrag D, et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient’s experience. Oncologist. 2013; 18 ( 4 ): 381 - 390. doi: 10.1634/theoncologist.2012-0279
dc.identifier.citedreferenceFenn KM, Evans SB, McCorkle R, et al. Impact of financial burden of cancer on survivors’ quality of life. J Oncol Pract. 2014; 10 ( 5 ): 332 - 338. doi: 10.1200/JOP.2013.001322
dc.identifier.citedreferenceZafar SY, McNeil RB, Thomas CM, Lathan CS, Ayanian JZ, Provenzale D. Population-based assessment of cancer survivors’ financial burden and quality of life: a prospective cohort study. J Oncol Pract. 2015; 11 ( 2 ): 145 - 150. doi: 10.1200/JOP.2014.001542
dc.identifier.citedreferenceRamsey S, Blough D, Kirchhoff A, et al. Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff (Millwood). 2013; 32 ( 6 ): 1143 - 1152. doi: 10.1377/hlthaff.2012.1263
dc.identifier.citedreferenceRamsey SD, Bansal A, Fedorenko CR, et al. Financial insolvency as a risk factor for early mortality among patients with cancer. J Clin Oncol. 2016; 34 ( 9 ): 980 - 986. doi: 10.1200/JCO.2015.64.6620
dc.identifier.citedreferenceGharzai LA, Ryan KA, Szczygiel L, et al. Financial toxicity during breast cancer treatment: a qualitative analysis to inform strategies for mitigation. JCO Oncol Pract. 2021; 17 ( 10 ): e1413 - e1423. doi: 10.1200/OP.21.00182
dc.identifier.citedreferenceKeehan SP, Stone DA, Poisal JA, et al. National health expenditure projections, 2016–25: price increases, aging push sector to 20 percent of economy. Health Aff (Millwood). 2017; 36 ( 3 ): 553 - 563. doi: 10.1377/hlthaff.2016.1627
dc.identifier.citedreferencePrasad V, De Jesus K, Mailankody S. The high price of anticancer drugs: origins, implications, barriers, solutions. Nat Rev Clin Oncol. 2017; 14 ( 6 ): 381 - 390. doi: 10.1038/nrclinonc.2017.31
dc.identifier.citedreferenceSaluja R, Arciero VS, Cheng S, et al. Examining trends in cost and clinical benefit of novel anticancer drugs over time. J Oncol Pract. 2018; 14 ( 5 ): e280 - e294. doi: 10.1200/JOP.17.00058
dc.identifier.citedreferenceChakma J, Sun GH, Steinberg JD, Sammut SM, Jagsi R. Asia’s ascent—global trends in biomedical R&D expenditures. N Engl J Med. 2014; 370 ( 1 ): 3 - 6. doi: 10.1056/NEJMp1311068
dc.identifier.citedreferenceDogan S, Yamamoto-Ibusuki M, Andre F. Funding sources of practice-changing trials. Ann Oncol. 2018; 29 ( 4 ): 1063 - 1065. doi: 10.1093/annonc/mdx798
dc.identifier.citedreferenceFilloon TG. Estimating the minimum therapeutically effective dose of a compound via regression modelling and percentile estimation. Stat Med. 1995; 14 ( 9-10 ): 925 - 932. doi: 10.1002/sim.4780140911
dc.identifier.citedreferenceWhelan T, MacKenzie R, Julian J, et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst. 2002; 94 ( 15 ): 1143 - 1150. doi: 10.1093/jnci/94.15.1143
dc.identifier.citedreferenceBentzen SM, Agrawal RK, Aird EGA, et al.; START Trialists’ Group. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol. 2008; 9 ( 4 ): 331 - 341. doi: 10.1016/S1470-2045(08)70077-9
dc.identifier.citedreferenceBentzen SM, Agrawal RK, Aird EGA, et al.; START Trialists’ Group. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008; 371 ( 9618 ): 1098 - 1107. doi: 10.1016/S0140-6736(08)60348-7
dc.identifier.citedreferenceJagsi R, Falchook AD, Hendrix LH, Curry H, Chen RC. Adoption of hypofractionated radiation therapy for breast cancer after publication of randomized trials. Int J Radiat Oncol Biol Phys. 2014; 90 ( 5 ): 1001 - 1009. doi: 10.1016/j.ijrobp.2014.09.032
dc.identifier.citedreferenceSmith BD, Bentzen SM, Correa CR, et al. Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Int J Radiat Oncol Biol Phys. 2011; 81 ( 1 ): 59 - 68. doi: 10.1016/j.ijrobp.2010.04.042
dc.identifier.citedreferenceBekelman JE, Sylwestrzak G, Barron J, et al. Uptake and costs of hypofractionated vs conventional whole breast irradiation after breast conserving surgery in the United States, 2008–2013. JAMA. 2014; 312 ( 23 ): 2542 - 2550. doi: 10.1001/jama.2014.16616
dc.identifier.citedreferenceWoodward SG, Varshney K, Anne PR, George BJ, Willis AI. Trends in use of hypofractionated whole breast radiation in breast cancer: an analysis of the National Cancer Database. Int J Radiat Oncol Biol Phys. 2021; 109 ( 2 ): 449 - 457. doi: 10.1016/j.ijrobp.2020.09.004
dc.identifier.citedreferenceMarta GN, Ramiah D, Kaidar-Person O, et al. The financial impact on reimbursement of moderately hypofractionated postoperative radiation therapy for breast cancer: an international consortium report. Clin Oncol. 2021; 33 ( 5 ): 322 - 330. doi: 10.1016/j.clon.2020.12.008
dc.identifier.citedreferenceJagsi R, Griffith KA, Boike TP, et al. Differences in the acute toxic effects of breast radiotherapy by fractionation schedule: comparative analysis of physician-assessed and patient-reported outcomes in a large multicenter cohort. JAMA Oncol. 2015; 1 ( 7 ): 918 - 930. doi: 10.1001/jamaoncol.2015.2590
dc.identifier.citedreferenceDearnaley D, Syndikus I, Mossop H, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016; 17 ( 8 ): 1047 - 1060. doi: 10.1016/S1470-2045(16)30102-4
dc.identifier.citedreferenceLee WR, Dignam JJ, Amin MB, et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol. 2016; 34 ( 20 ): 2325 - 2332. doi: 10.1200/JCO.2016.67.0448
dc.identifier.citedreferenceJackson WC, Silva J, Hartman HE, et al. Stereotactic body radiation therapy for localized prostate cancer: a systematic review and meta-analysis of over 6,000 patients treated on prospective studies. Int J Radiat Oncol Biol Phys. 2019; 104 ( 4 ): 778 - 789. doi: 10.1016/j.ijrobp.2019.03.051
dc.identifier.citedreferenceLee A, Shah K, Chino F. Assessment of parking fees at National Cancer Institute-designated cancer treatment centers. JAMA Oncol. 2020; 6 ( 8 ): 1295 - 1297. doi: 10.1001/jamaoncol.2020.1475
dc.identifier.citedreferenceTemkin E, Trinh J. FDA’s accelerated approval pathway: a rare disease perspective. National Organization for Rare Disorders. Accessed March 25, 2022. https://rarediseases.org/wp-content/uploads/2021/06/NRD-2182-Policy-Report_Accelerated-Approval_FNL.pdf
dc.identifier.citedreferenceGyawali B, Hey SP, Kesselheim AS. Evaluating the evidence behind the surrogate measures included in the FDA’s table of surrogate endpoints as supporting approval of cancer drugs. EClinicalMedicine. 2020; 21: 100332. doi: 10.1016/j.eclinm.2020.100332
dc.identifier.citedreferenceChen EY, Haslam A, Prasad V. FDA acceptance of surrogate end points for cancer drug approval: 1992-2019. JAMA Intern Med. 2020; 180 ( 6 ): 912. doi: 10.1001/jamainternmed.2020.1097
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncr34677_am.pdf
Size:
410.2KB
Format:
PDF
View/Open
Name:
cncr34677.pdf
Size:
268.2KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.